Monitor the final pricing and share count of this offering to assess dilution magnitude relative to the $172M market cap. The company's ability to successfully commercialize VOCERYQ and achieve profitability is critical given the going concern warning and frequent capital raises.
Drug in focus
INO drug pipeline →VOCERYQ
● Neutral Named in this 424B5- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
- Next catalyst
- None dated
What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $1.22entry
- T+1 · 8d ago +24.28%α +21.91% · $1.51
- T+5 · 4d ago +17.70%α +15.10% · $1.43
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Inovio Pharmaceuticals filed a preliminary prospectus supplement for an underwritten public offering of common stock, with share count, price, and proceeds left as placeholders (TBD). The offering follows the October 30, 2026 FDA accelerated approval of its first commercial product VOCERYQ (INO-3107) for RRP, and comes as the company reported a preliminary cash balance of $48.4M as of September 30, 2026, with a going concern warning. The filing is a priced equity offering from the $300M shelf, underwritten by Jefferies and Piper Sandler, with a 90-day lock-up for the company and insiders.
Key Financial Metrics
Key Facts
- Preliminary prospectus supplement for an underwritten common stock offering, with share count, price, and proceeds all TBD (placeholders).
- Last reported sale price on November 4, 2026 was $1.62 per share.
- Underwriters: Jefferies LLC and Piper Sandler & Co. as joint book-running managers; 30-day option for additional shares (amount TBD).
- 90-day lock-up for the company, executive officers, and directors.
- Proceeds intended to fund commercial launch of VOCERYQ, clinical pipeline development, and general corporate purposes.
- FDA approved VOCERYQ (INO-3107) under accelerated approval on October 30, 2026 for RRP.
- Preliminary cash, cash equivalents, and short-term investments of $48.4M as of September 30, 2026.
- Company states substantial doubt exists about its ability to continue as a going concern.
- 110,181,507 shares outstanding as of September 30, 2026; massive warrant overhang (over 94M shares underlying warrants at various exercise prices).
- 12 offering/registration filings in the last 24 months; market cap $172M.
Financial Impact
Offering size TBD; proceeds will be used to fund VOCERYQ launch and pipeline; company had $48.4M cash as of September 30, 2026.
Risk Factors
- Offering size and price are TBD; final terms will determine dilution severity.
- Company has a going concern warning and a history of frequent dilutive offerings.
- Massive warrant overhang (over 94M shares) could lead to further dilution upon exercise.
- VOCERYQ commercial launch is early-stage and faces competition from PAPZIMEOS.
- Accelerated approval of VOCERYQ is contingent on confirmatory trial results; failure could lead to withdrawal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-449837 |
| Document: 0001193125-26-449837-index-headers.html | 0001193125-26-449837 |
| Document: 0001193125-26-449837-index.html | 0001193125-26-449837 |
| Document: 0001193125-26-449837.txt | 0001193125-26-449837 |
Track record
20 reports on INO
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
- Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
- Nov 5, 202611d ago Press Release Bearish 6/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 4/10 Viewing Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
- Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers